Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faceptor vs Herceptin in HER2+ Metastatic Breast Cancer
NCT05301010Phase 3Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Nanogen Pharmaceutical Biotechnology JSC. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05301010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301010.